426 related articles for article (PubMed ID: 23053656)
41. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
42. Activation of AMPK/TSC2/PLD by alcohol regulates mTORC1 and mTORC2 assembly in C2C12 myocytes.
Hong-Brown LQ; Brown CR; Navaratnarajah M; Lang CH
Alcohol Clin Exp Res; 2013 Nov; 37(11):1849-61. PubMed ID: 23895284
[TBL] [Abstract][Full Text] [Related]
43. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
44. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
Hassan B; Akcakanat A; Sangai T; Evans KW; Adkins F; Eterovic AK; Zhao H; Chen K; Chen H; Do KA; Xie SM; Holder AM; Naing A; Mills GB; Meric-Bernstam F
Oncotarget; 2014 Sep; 5(18):8544-57. PubMed ID: 25261369
[TBL] [Abstract][Full Text] [Related]
45. Tumor necrosis factor-alpha (TNF-α)-mediated in vitro human retinal pigment epithelial (RPE) cell migration mainly requires Akt/mTOR complex 1 (mTORC1), but not mTOR complex 2 (mTORC2) signaling.
Liu Y; Cao GF; Xue J; Wan J; Wan Y; Jiang Q; Yao J
Eur J Cell Biol; 2012 Sep; 91(9):728-37. PubMed ID: 22595285
[TBL] [Abstract][Full Text] [Related]
46. Signal transduction pathways in FSH regulation of rat Sertoli cell proliferation.
Riera MF; Regueira M; Galardo MN; Pellizzari EH; Meroni SB; Cigorraga SB
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E914-23. PubMed ID: 22275758
[TBL] [Abstract][Full Text] [Related]
47. Fetal brain mTOR signaling activation in tuberous sclerosis complex.
Tsai V; Parker WE; Orlova KA; Baybis M; Chi AW; Berg BD; Birnbaum JF; Estevez J; Okochi K; Sarnat HB; Flores-Sarnat L; Aronica E; Crino PB
Cereb Cortex; 2014 Feb; 24(2):315-27. PubMed ID: 23081885
[TBL] [Abstract][Full Text] [Related]
48. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
[TBL] [Abstract][Full Text] [Related]
49. Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway.
Chang H; Peng X; Bai Q; Zhou Y; Yu X; Zhang Q; Zhu J; Mi M
Carcinogenesis; 2014 Aug; 35(8):1847-54. PubMed ID: 24861637
[TBL] [Abstract][Full Text] [Related]
50. Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
Wang Y; Wei J; Li L; Fan C; Sun Y
Oncol Res; 2014; 22(4):193-201. PubMed ID: 26351208
[TBL] [Abstract][Full Text] [Related]
51. Anthocyanins are novel AMPKα1 stimulators that suppress tumor growth by inhibiting mTOR phosphorylation.
Lee YK; Lee WS; Kim GS; Park OJ
Oncol Rep; 2010 Dec; 24(6):1471-7. PubMed ID: 21042741
[TBL] [Abstract][Full Text] [Related]
52. Improvement of mTORC1-driven overproduction of apoB-containing triacylglyceride-rich lipoproteins by short-chain fatty acids, 4-phenylbutyric acid and (R)-α-lipoic acid, in human hepatocellular carcinoma cells.
Roberts JL; He B; Erickson A; Moreau R
Biochim Biophys Acta; 2016 Mar; 1861(3):166-76. PubMed ID: 26680362
[TBL] [Abstract][Full Text] [Related]
53. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
[TBL] [Abstract][Full Text] [Related]
55. Acidic tumor microenvironment abrogates the efficacy of mTORC1 inhibitors.
Faes S; Duval AP; Planche A; Uldry E; Santoro T; Pythoud C; Stehle JC; Horlbeck J; Letovanec I; Riggi N; Demartines N; Dormond O
Mol Cancer; 2016 Dec; 15(1):78. PubMed ID: 27919264
[TBL] [Abstract][Full Text] [Related]
56. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
57. Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model.
Lamming DW; Cummings NE; Rastelli AL; Gao F; Cava E; Bertozzi B; Spelta F; Pili R; Fontana L
Oncotarget; 2015 Oct; 6(31):31233-40. PubMed ID: 26378060
[TBL] [Abstract][Full Text] [Related]
58. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.
Henry WS; Laszewski T; Tsang T; Beca F; Beck AH; McAllister SS; Toker A
Cancer Res; 2017 Feb; 77(3):790-801. PubMed ID: 27940576
[TBL] [Abstract][Full Text] [Related]
59. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.
Meyer GE; Chesler L; Liu D; Gable K; Maddux BA; Goldenberg DD; Youngren JF; Goldfine ID; Weiss WA; Matthay KK; Rosenthal SM
J Cell Biochem; 2007 Dec; 102(6):1529-41. PubMed ID: 17486636
[TBL] [Abstract][Full Text] [Related]
60. Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPKalpha1.
Lee YK; Park SY; Kim YM; Kim DC; Lee WS; Surh YJ; Park OJ
Carcinogenesis; 2010 Jun; 31(6):1092-9. PubMed ID: 20164123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
